http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
PDS Biotech Announces Initiation of Phase 2 Trial of PDS0101 in Combination with Standard of Care Chemoradiotherapy in Advanced Cervical Cancer
-
PDS Biotechnology Announces Participation in Noble Capital Markets Virtual Road Show Series
-
PDS Biotechnology Announces Participation in Noble Capital Markets C-Suite Interview Series
-
PDS Biotechnology Reports Financial Results for the Second Quarter 2020 and Provides Business Update
-
PDS Biotechnology Announces Conference Call and Webcast for Second Quarter 2020 Financial Results
-
PDS Biotechnology (PDSB) Announces Preclinical Data for PDS0203, T-Cell Activating Recombinant Protein Vaccine Against COVID-19
-
PDS Biotech Announces Preclinical Data for PDS0203, a T-Cell Activating Recombinant Protein Vaccine Against COVID-19
-
PDS Biotechnology (PDSB) Collaborator Granted NIAID Award to Accelerate Development of Versamune®-Based Universal Influenza Vaccine
-
PDS Biotech Collaborator Granted NIAID Award to Accelerate Development of Versamune®-Based Universal Influenza Vaccine
-
PDS Biotech Announces Publication of Preclinical Results of PDS0101 Combination by the National Cancer Institute in the Journal for ImmunoTherapy of Cancer
-
PDS Biotechnology (PDSB), Farmacore Biotechnology Announce Co-Development of PDS0204 COVID-19 Vaccine
-
PDS Biotechnology and Farmacore Biotechnology Announce Co-Development of PDS0204 COVID-19 Vaccine
-
PDS Biotechnology (PDSB) Begins Phase 2 Trial of PDS0101 Led by the National Cancer Institute
-
PDS Biotech Announces Initiation of Phase 2 Trial of PDS0101 Led by the National Cancer Institute
-
PDS Biotech Announces Clinical Trial of Its Lead Immunotherapy Product, PDS0101, in Combination with Chemoradiotherapy in Advanced Cervical Cancer
-
PDS Biotechnology to Present at the 2020 Virtual Investor Summit
-
PDS Biotechnology (PDSB) Announces Publication at American Society of Clinical Oncology ASCO
-
PDS Biotechnology Announces Publication at American Society of Clinical Oncology (ASCO) 2020
-
PDS Biotechnology Reports Financial Results for the First Quarter 2020 and Provides Business Update
-
PDS Biotechnology Announces Conference Call and Webcast for First Quarter 2020 Financial Results
-
PDS Biotechnology Expands CRADA with the National Cancer Institute to Include Second Versamune®-Based Anti-Cancer Product
-
PDS Biotechnology Initiates Novel Vaccine Development Programs For COVID-19 and Universal Influenza; Delay of PDS0101 VERSATILE-002 trial
-
PDS Biotechnology (PDSB) Adds Dr. Ilian Iliev to Board
-
PDS Biotechnology Appoints Dr. Ilian Iliev to Board of Directors
-
PDS Biotechnology Reports Full Year 2019 Financial Results and Provides Business Update
-
PDS Biotechnology Announces Resignation of Andrew Saik as CFO
-
PDS Biotechnology (PDSB) Expands Patent Portfolio for its Novel Versamune Platform
-
PDS Biotechnology Expands Patent Portfolio for its Novel Versamune® Platform
-
PDS Biotechnology Announces Commencement of Work Under a Pre-Clinical Collaboration with Farmacore Biotechnology for Tuberculosis
-
PDS Biotechnology (PDSB) Names Kamil Ali-Jackson Esq. to Board
-
PDS Biotechnology Appoints Kamil Ali-Jackson, Esq. to Board of Directors
-
PDS Biotechnology to Present at Noble Capital Markets' 16th Annual Small & Microcap Investor Conference
-
PDS Biotechnology Corporation Announces Closing of Public Offering
-
PDS Biotechnology to Present at the 2020 BIO CEO & Investor Conference
-
PDS Biotechnology to Present at the 2020 BIO CEO & Investor Conference
-
PDS Biotechnology Announces Principal Investigator and Independent Data Monitoring Committee for its Phase 2 Clinical Collaboration with Merck
-
PDS Biotechnology (PDSB) Reports Resignation of James Loughlin from Board
-
PDS Biotechnology Announces Resignation of James Loughlin from Board of Directors
-
PDS Biotechnology to Present at the 12th Annual LD Micro Main Event
-
PDS Biotechnology to Present at the World Vaccine & Immunotherapy Congress West Coast 2019

